HomeAI · summaries
Storia in 2 fonti
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
- ·
upi.com
FDA moves to exclude weight loss drugs from compounding chemicals list - UPI.com
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.